{
  "docId": "019de076-7b67-762e-8b55-8f35aa9a2cc0",
  "docSlug": "7d5a5b546ee496a809a6ede1a6c2c260",
  "documentTitle": "Equillium | Investor Presentation Deck | 32 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 32,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "other",
  "function": "other",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide details a specific corporate partnership agreement.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7b67-762e-8b55-8f35aa9a2cc0/6",
  "deckHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0",
  "deckJsonHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0.json",
  "deckAnchorHref": "/decks/019de076-7b67-762e-8b55-8f35aa9a2cc0#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.0018
      },
      "kind": "callout",
      "text": "Equillium receives upfront payment and full funding of itolizumab R&D in exchange for Ono exclusive option to purchase Equillium’s rights to itolizumab",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b464b214-10d2-431c-8c1d-a9c63ff09289",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.0094
      },
      "kind": "disclaimer",
      "text": "* Includes upfront payment of $26.4M and R&D expense reimbursement for the period July 1 through December 31, 2022.\n** ¥5.0B subject to currency exchange rate at the time of payment (USD amount above is based on the exchange rate as of November 3, 2023); milestone payments and R&D reimbursement are based in USD.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42453833-416e-4874-9e22-9a12f330f924",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.3,
        "x": 0.62,
        "y": 0.0035
      },
      "kind": "image",
      "text": "ONO PHARMACEUTICAL CO.,LTD.",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2257e1df-292d-4a05-b761-5e7b23e9b116",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.05,
        "y": 0.005
      },
      "kind": "list",
      "text": "Itolizumab development and funding:\n- Equillium to continue conducting all itolizumab R&D\n- Ono to fund all R&D expenses from July 1, 2022 through the option period\n- R&D budget approximately $8M per quarter",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34510443-1781-4000-b67a-9af94a55221d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.05,
        "y": 0.0035
      },
      "kind": "list",
      "text": "Closing payments*: $38.2M\nOption exercise payment**: $33.3M\nMilestone payments: $101.4M",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70991cda-2dcf-4a02-8213-6f98f24752e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.62,
        "y": 0.0045
      },
      "kind": "list",
      "text": "Option period expires three months following delivery of:\n- topline data from the EQUALISE study in lupus nephritis, and\n- interim data from the EQUATOR study in acute GVHD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b8a64401-34e8-4bdf-a114-b7df0eb8d5d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.05,
        "y": 0.0072
      },
      "kind": "list",
      "text": "Milestone Payments up to $101.4M:\n- Clinical - Regulatory - First sale",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e81c510b-dc23-42cb-985d-cccd9b64631c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.78,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Ono Pharmaceutical: High Value Strategic Partnership",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d65d49d1-7a49-4d2b-a07c-8f0e31f6316d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Call to action",
      "slug": "call-to-action",
      "agent": null,
      "layer": "slide",
      "matchId": "3b05442f-76e4-4ffd-9c88-042b3e4a254a",
      "evidence": "The slide mentions an option period and payments, implying a call to action.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 5,
      "beatId": "ad87164c-eefb-4286-988c-3da24e7ea3ff",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 5-23 present Equillium's platform and pipeline as a solution to the problems identified, providing relief for patients with immunological disorders.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}